Bio-Rad Laboratories Inc (BIO)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	2,637,846	2,686,946	2,731,337	2,741,910	2,774,598	2,777,098	2,856,467	2,894,713	2,922,702	2,979,702	2,876,119	2,701,076	2,540,271	2,374,971	2,288,622	2,311,881	2,292,289	2,284,689	2,267,881	2,271,474
Receivables	US$ in thousands	500,917	468,602	500,675	513,073	506,245	440,802	456,624	470,707	425,737	419,614	401,207	409,537	420,824	403,741	362,554	382,376	392,672	356,025	377,904	391,699
Receivables turnover		5.27	5.73	5.46	5.34	5.48	6.30	6.26	6.15	6.87	7.10	7.17	6.60	6.04	5.88	6.31	6.05	5.84	6.42	6.00	5.80

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $2,637,846K ÷ $500,917K
= 5.27

Bio-Rad Laboratories Inc.'s receivables turnover ratio has been relatively stable over the past eight quarters, ranging from a low of 5.46 in Q4 2023 to a high of 6.49 in Q3 2022. This indicates that the company collects its accounts receivable approximately 5 to 6 times per year on average. A higher turnover ratio suggests a more efficient management of receivables, as the company is collecting payments more frequently. However, a slight decline in the ratio from Q3 2022 to Q4 2023 may suggest a potential slowdown in the collection of receivables, which could impact the company's liquidity and cash flow. Further investigation into the reasons behind this trend may be required to assess the overall financial health and efficiency of Bio-Rad Laboratories Inc. regarding its accounts receivable management.